Here, we report that depletion of USP29 is sufficient to re-sensitize HCC cells to Sorafenib in vitro and in vivo, suggesting that USP29 is a novel and suitable target for overcoming Sorafenib resistance in HCC. Here, USP29 is linked to hepatocellular carcinoma.